NexImmune deal

An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer, former Celgene Corp. (NASDAQ:CELG, Summit, N.J.) chairman and CEO

Read the full 256 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE